IP Library Granted Patent US 8,795,685
Granted Patent B2
US 8,795,685 · App. 11/660,449 · Granted Aug 5, 2014

Mutated HIV Nef for modulating immunity

Inventors: Martial Renard (Paris, FR); Marianne Mangeney (Paris, FR); Thierry Heidmann (Paris, FR)
Assignees: Institut Gustave Roussy; Centre National de la Recherche Scientifique; Universite Paris Sud XI
A61K39/21A61K38/162A61K2300/00C07K14/161C07K14/162C07K14/163
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,795,685
App. No.
11/660,449
Granted
Aug 5, 2014
Kind
B2
Abstract

Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.

Claims (30)

1. A composition comprising a pharmaceutically acceptable carrier and a mutated Nef protein having substantially no immunosuppressive activity,

said mutated Nef protein being obtained by substitution of one amino acid of the immunosuppressive domain of a wild type Nef protein having an immunosuppressive domain that differs from the immunosuppressive domain of a non-mutated wild type Nef protein by a substitution of one amino acid of the immunosuppressive domain of said wild type Nef protein, said wild type Nef protein being constituted by one of the amino acid sequences of the group consisting of SEQ ID NO: 1, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, or SEQ ID NO: 290,

said mutated Nef protein having substantially preserved CD4 and/or MHC-I downregulation functions with respect to the non mutated Nef protein,

wherein

the one amino acid is selected from the group consisting of:

the amino acid at position 93 of one of SEQ ID NO: 1, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279,

the amino acid at position 94 of SEQ ID NO: 276,

the amino acid at position 96 of SEQ ID NO: 281,

the amino acid at position 103 of SEQ ID NO: 280,

the amino acid at position 124 of SEQ ID NO: 287, and

the amino acid at position 125 of one of SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 288, SEQ ID NO: 289, and SEQ ID NO: 290;

the one amino acid is substituted by one of R, H and K; and

said mutated NEF protein varies from said wild type NEF protein by said substitution of said one amino acid in said immunosuppressive domain.

2. The composition according to claim 1 , wherein the one amino acid is substituted by R.

3. The composition according to claim 1 , comprising as active substance a mutated Nef protein as set forth in SEQ ID NO: 2.

4. The composition according to claim 1 , further comprising at least one HIV protein, or a fragment thereof, or one HIV lipopeptide, or a fragment thereof.

5. The composition according to claim 4 , wherein said HIV protein is chosen among gp41, gp120, gp140, gp160, Env, Gag, Pol, Rev, RT, Vpu and Tat.

6. A protein comprising the sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 31.

7. A composition comprising a pharmaceutically acceptable carrier and a mutated Nef protein having substantially no immunosuppressive activity,

said mutated Nef protein being obtained by substitution of one amino acid of the immunosuppressive domain of a wild type Nef protein, provided that the substitution substantially preserves CD4 and/or MHC-I downregulation functions with respect to said wild type Nef protein, said wild type Nef protein being constituted by one of the amino acid sequences of the group consisting of SEQ ID NO: 1, SEQ ID NO: 275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280, SEQ ID NO: 281, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, or SEQ ID NO: 290,

wherein

the one amino acid is selected from the group consisting of:

the amino acid at position 93 of one of SEQ ID NO: 1, SEQ ID NO: 275, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279,

the amino acid at position 94 of SEQ ID NO: 276,

the amino acid at position 96 of SEQ ID NO: 281,

the amino acid at position 103 of SEQ ID NO: 280,

the amino acid at position 124 of SEQ ID NO: 287, and

the amino acid at position 125 of one of SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 288, SEQ ID NO: 289, and SEQ ID NO: 290;

the one amino acid is substituted by one of R, H and K; and

said mutated NEF protein varies from said wild type NEF protein by said substitution of said one amino acid in said immunosuppressive domain.

Assignments (2)
MERGER Recorded Oct 20, 2021
From: UNIVERSITE PARIS SUD XI
To: UNIVERSITE PARIS-SACLAY
Reel/Frame 057847/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2007
From: RENARD, MARTIAL; MANGENEY, MARIANNE; HEIDMANN, THIERRY
To: INSTITUT GUSTAVE ROUSSY; CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PARIS SUD XI
Reel/Frame 019309/0631 →
Priority Claims (1)
EP 04292056 · Aug 17, 2004 · regional
Continuity (1)
Related Publication 20080220008A1 · Sep 11, 2008